Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer

Abstract Background Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) often develops resistance to endocrine therapy (ET), necessitating targeted therapies like Palbociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor). Thi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nadia Najafizade, Shadi Zarei, Mohammadreza Elhaie, Mahnaz Roayaei
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2025-12-01
coleção:	Discover Oncology
Assuntos:	Breast neoplasms Hormone receptor positive breast cancer Metastatic breast cancer Palbociclib Everolimus
Acesso em linha:	https://doi.org/10.1007/s12672-025-04330-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!